Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients ...

ITM announces positive Phase 3 results for ITM-11 in neuroendocrine tumours, paving the way for a potential new treatment ...

Rare cancers are less known and pose challenges due to limited research and diagnostic difficulties. Environmental factors, ...

Dr. Jonathan R. Strosberg, discussed results of the CABINET trial evaluating Cabometyx versus placebo in advanced ...

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...

After 20 years of building radioisotope expertise as a manufacturer and supplier, German firm ITM Isotope Technologies is ...

Comparative outcomes of neuroendocrine tumors in the historically underserved population of Bronx, NY: Montefiore Einstein Comprehensive Cancer Center. Pamrevlumab ...

Effect of marital status and race on survival of patients with well differentiated neuroendocrine tumors (NETs). Clinicopathological factors related to survival in gastroenteropancreatic ...

Discover ITM and its cancer candidate ITM-11 as it brings one of the first big wins the radiopharmaceutical sector awaits.

ITM's lutetium-containing therapy extended progression-free survival versus everolimus in patients with a specific kind of ...

Topline results from the COMPETE trial showed that ITM-11 met the study’s primary end point of PFS in inoperable, progressive ...